Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma
Tom Martin(UCSF Helen Diller Family Comprehensive Cancer Center), Imtiaz A. Samjoo(EVERSANA (Canada)), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center), Joris Diels(Janssen (Belgium)), Anja Haltner(EVERSANA (Canada)), Suzy Van Sanden(Janssen (Belgium)), Satish Valluri(Janssen (United States)), Ashraf Garrett, Arnob Banerjee(Johnson & Johnson (United States)), Chris Cameron(St. Michael's Hospital), Jordan M. Schecter(Centro de Investigación del Cáncer), William Deraedt(Janssen (Belgium)), Hong Tian(Massey University), Tzu‐Min Yeh(Centro de Investigación del Cáncer), Martin Vogel(Janssen (United States)), Lida Pacaud(Centro de Investigación del Cáncer), Carolyn C. Jackson(Centro de Investigación del Cáncer)
Cited by 49
Related Papers
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
|Annals of Internal Medicine|2015|8.2k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719